{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:41:33Z","timestamp":1789594893846,"version":"build-2803163510"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.parkreldis.2018.10.006","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T02:29:14Z","timestamp":1538533754000},"page":"101-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Progress in the treatment of Parkinson-Plus syndromes"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-2490","authenticated-orcid":false,"given":"Nahid","family":"Olfati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shoeibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-3445","authenticated-orcid":false,"given":"Irene","family":"Litvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2018.10.006_bib1","series-title":"Atypical Parkinsonian Disorders - Clinical and Research Aspects","first-page":"1","article-title":"What is an atypical parkinsonian disorder?","author":"Litvan","year":"2005"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.23713","article-title":"Milestones in atypical and secondary Parkinsonisms","volume":"26","author":"Wenning","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/CON.0000000000000348","article-title":"Diagnostic approach to atypical parkinsonian syndromes","volume":"22","author":"McFarland","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib4","series-title":"Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism","author":"Giagkou","year":"2018"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib6","series-title":"Multiple System Atrophy","first-page":"97","article-title":"Clinical presentation","author":"Fanciulli","year":"2014"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/NEN.0b013e31817d7a1d","article-title":"Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases","volume":"67","author":"Fujishiro","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/glia.22653","article-title":"Alpha-synuclein mRNA expression in oligodendrocytes in MSA","volume":"62","author":"Asi","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/glia.22611","article-title":"Alpha-synuclein transfers from neurons to oligodendrocytes","volume":"62","author":"Reyes","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature10324","article-title":"alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation","volume":"477","author":"Bartels","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib12","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024091","article-title":"Cell biology and pathophysiology of alpha-synuclein","volume":"8","author":"Burre","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib13","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"Ueda","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JPD-150642","article-title":"The synaptic function of alpha-synuclein","volume":"5","author":"Burre","year":"2015","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00401-002-0651-4","article-title":"Clinical and neuropathological correlates of Lewy body disease","volume":"105","author":"Hishikawa","year":"2003","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib16","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1093\/brain\/awh303","article-title":"The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations","volume":"127","author":"Ozawa","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib17","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.bbadis.2008.07.006","article-title":"A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders","volume":"1792","author":"Jellinger","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib18","first-page":"771","article-title":"Decreased beta-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy","volume":"145","author":"Chui","year":"1994","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib19","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1074\/jbc.271.12.6839","article-title":"Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger","volume":"271","author":"Tomiyama","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib20","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","article-title":"Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils","volume":"11","author":"Li","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib21","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/WNR.0b013e32830b3661","article-title":"Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy","volume":"19","author":"Ubhi","year":"2008","journal-title":"Neuroreport"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","article-title":"Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial","volume":"13","author":"Low","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib23","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib24","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.febslet.2011.03.046","article-title":"Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds","volume":"585","author":"Caruana","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00702-016-1507-8","article-title":"The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach","volume":"123","author":"Levin","year":"2016","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib26","series-title":"21st International Congress of Parkinson's Disease and Movement Disorders","article-title":"PROMESA: progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach \u2013 evaluation of serious adverse events [abstract]","author":"Schuberth","year":"2017"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12031-012-9733-5","article-title":"Involvement of macroautophagy in multiple system atrophy and protein aggregate formation in oligodendrocytes","volume":"47","author":"Schwarz","year":"2012","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib28","doi-asserted-by":"crossref","first-page":"25009","DOI":"10.1074\/jbc.M300227200","article-title":"Alpha-Synuclein is degraded by both autophagy and the proteasome","volume":"278","author":"Webb","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib29","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4161\/auto.19371","article-title":"Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway","volume":"8","author":"Klucken","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib31","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1038\/emm.2013.45","article-title":"Autophagic failure promotes the exocytosis and intercellular transfer of alpha-synuclein","volume":"45","author":"Lee","year":"2013","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1083\/jcb.200504035","article-title":"Lithium induces autophagy by inhibiting inositol monophosphatase","volume":"170","author":"Sarkar","year":"2005","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jnnp-2011-302021","article-title":"Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial","volume":"83","author":"Verstraete","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/JAD-150437","article-title":"Lithium as a treatment for alzheimer's disease: a systematic review and meta-analysis","volume":"48","author":"Matsunaga","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00415-012-6655-7","article-title":"A randomized clinical trial of lithium in multiple system atrophy","volume":"260","author":"Sacca","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib36","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib39","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib40","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature14547","article-title":"alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00441-018-2839-5","article-title":"a-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences","volume":"373","author":"Peelaerts","year":"2018","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib43","author":"Affiris"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib44","series-title":"AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs\u00ae PD01A and PD03A, Confirming Safety and Tolerability for Both Compounds as Well as Immunogenicity for PD01A in Early MSA Patients","author":"Affiris","year":"2018"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib45","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1212\/01.WNL.0000078192.95645.E6","article-title":"[11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy","volume":"61","author":"Gerhard","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jnen\/63.1.43","article-title":"Microglial activation parallels system degeneration in multiple system atrophy","volume":"63","author":"Ishizawa","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib47","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","article-title":"Differential roles of M1 and M2 microglia in neurodegenerative diseases","volume":"53","author":"Tang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12640-015-9547-7","article-title":"Failure of neuroprotection despite microglial suppression by delayed-start myeloperoxidase inhibition in a model of advanced multiple system atrophy: clinical implications","volume":"28","author":"Kaindlstorfer","year":"2015","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12640-011-9294-3","article-title":"Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model","volume":"21","author":"Stefanova","year":"2012","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mds.22732","article-title":"Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial)","volume":"25","author":"Dodel","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib51","author":"Biohaven"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2377-12-131","article-title":"Treatment of multiple system atrophy using intravenous immunoglobulin","volume":"12","author":"Novak","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib53","first-page":"161","article-title":"Growth hormone: neurocrine and neuroendocrine perspectives","volume":"3","author":"Harvey","year":"1993","journal-title":"Growth Regul."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib54","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1523\/JNEUROSCI.20-08-02896.2000","article-title":"Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus","volume":"20","author":"Aberg","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib55","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1210\/en.2002-220667","article-title":"Growth hormone action on proliferation and differentiation of cerebral cortical cells from fetal rat","volume":"144","author":"Ajo","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib56","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.21501","article-title":"Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study","volume":"22","author":"Holmberg","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib57","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1471-4159.2006.03711.x","article-title":"Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells","volume":"97","author":"Caumont","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib58","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1111\/j.1460-9568.2006.05218.x","article-title":"Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro","volume":"24","author":"Shortland","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib59","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00702-004-0206-z","article-title":"Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice","volume":"112","author":"Diguet","year":"2005","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib60","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00702-004-0245-5","article-title":"Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (Parkinson variant of multiple system atrophy)","volume":"112","author":"Scherfler","year":"2005","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study","volume":"132","author":"Bensimon","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib62","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","article-title":"Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B","volume":"132","author":"Youdim","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib63","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1015131516649","article-title":"Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]","volume":"21","author":"Youdim","year":"2001","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.expneurol.2007.11.022","article-title":"Rasagiline is neuroprotective in a transgenic model of multiple system atrophy","volume":"210","author":"Stefanova","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(14)70288-1","article-title":"Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial","volume":"14","author":"Poewe","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.expneurol.2012.01.008","article-title":"Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy","volume":"234","author":"Ubhi","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/glia.22610","article-title":"Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy","volume":"62","author":"Valera","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.autneu.2017.09.016","article-title":"Translational therapies for multiple system atrophy: bottlenecks and future directions","volume":"211","author":"Stefanova","year":"2018","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib69","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.clpt.6100386","article-title":"Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy","volume":"83","author":"Lee","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","article-title":"A randomized trial of mesenchymal stem cells in multiple system atrophy","volume":"72","author":"Lee","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib71","series-title":"21st International Congress of Parkinson's Disease and Movement Disorders","article-title":"Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy \u2013 a phase I\/II dose-escalation trial [abstract]","author":"Singer","year":"2017"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib72","series-title":"70th AAN Annual Meeting, Neurology, Los Angeles","article-title":"Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy results in growth factor spike [abstract]","author":"Singer","year":"2018"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib73","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/mds.23556","article-title":"Uric acid as a potential disease modifier in patients with multiple system atrophy","volume":"26","author":"Lee","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib74","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00415-013-7006-z","article-title":"Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population","volume":"260","author":"Cao","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jns.2015.11.025","article-title":"Association of serum uric acid level with cognitive function among patients with multiple system atrophy","volume":"359","author":"Cao","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib76","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fnagi.2017.00247","article-title":"Contra-directional expression of serum homocysteine and uric acid as important biomarkers of multiple system atrophy severity: a cross-sectional study","volume":"9","author":"Chen","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clineuro.2017.04.002","article-title":"Serum uric acid level is linked to the disease progression rate in male patients with multiple system atrophy","volume":"158","author":"Fukae","year":"2017","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib78","doi-asserted-by":"crossref","first-page":"9593","DOI":"10.1073\/pnas.1609291113","article-title":"Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy","volume":"113","author":"Bassil","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fnins.2016.00099","article-title":"Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy","volume":"10","author":"Fellner","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib80","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1073\/pnas.1610099113","article-title":"Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein alpha-synuclein","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib81","series-title":"The 13th International Congress of Alzheimer's and Parkinson's DiseasesVienna, Austria","first-page":"58","article-title":"Targeting alpha-synuclein pathology with the molecular tweezer CLR01 in multiple system atrophy","author":"Stefanova","year":"2017"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib82","doi-asserted-by":"crossref","first-page":"16233","DOI":"10.1021\/bi048453u","article-title":"Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro","volume":"43","author":"Hoyer","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib83","doi-asserted-by":"crossref","first-page":"22670","DOI":"10.1074\/jbc.M501508200","article-title":"A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease","volume":"280","author":"Liu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1460-9568.2010.07284.x","article-title":"Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology","volume":"32","author":"Ulusoy","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib85","series-title":"A Small Molecule Inhibitor of Caspase 1, Probe Reports from the NIH Molecular Libraries Program, Bethesda (MD)","author":"Boxer","year":"2010"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib86","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fnmol.2017.00329","article-title":"MicroRNA-101 modulates autophagy and oligodendroglial alpha-synuclein accumulation in multiple system atrophy","volume":"10","author":"Valera","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib87","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib88","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinson's Dis."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib89","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2017.09.013","article-title":"A case report of multiple system atrophy treated with an Abelson tyrosine kinase inhibitor","volume":"382","author":"Ngoc","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib90","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s004010050004","article-title":"Glial cell line-derived neurotrophic factor-like immunoreactivity in the cerebella of normal subjects and patients with multiple system atrophy","volume":"100","author":"Kawamoto","year":"2000","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib91","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1523\/JNEUROSCI.0567-10.2010","article-title":"Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors","volume":"30","author":"Ubhi","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib92","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1212\/WNL.0000000000003221","article-title":"A genome-wide association study in multiple system atrophy","volume":"87","author":"Sailer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib93","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/hmg\/ddl243","article-title":"Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity","volume":"15","author":"Kontopoulos","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib94","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S1474-4422(09)70262-5","article-title":"Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies","volume":"8","author":"Urdinguio","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib95","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5607\/en.2014.23.4.277","article-title":"Multiple system atrophy: genetic or epigenetic?","volume":"23","author":"Sturm","year":"2014","journal-title":"Exp Neurobiol"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib96","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s13311-016-0447-1","article-title":"Neuroprotection by epigenetic modulation in a transgenic model of multiple system atrophy","volume":"13","author":"Sturm","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib97","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","article-title":"Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?","volume":"16","author":"Jellinger","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib98","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","article-title":"Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein","volume":"182","author":"Games","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib99","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jnc.12175","article-title":"Monoclonal antibodies selective for alpha-synuclein oligomers\/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation","volume":"126","author":"Fagerqvist","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/13506129.2013.835726","article-title":"Off-pathway alpha-synuclein oligomers seem to alter alpha-synuclein turnover in a cell model but lack seeding capability in vivo","volume":"20","author":"Fagerqvist","year":"2013","journal-title":"Amyloid"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib101","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2014.05.009","article-title":"Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice","volume":"69","author":"Lindstrom","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib102","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fnins.2016.00408","article-title":"Alpha-synuclein oligomers-neurotoxic molecules in Parkinson's disease and other Lewy body disorders","volume":"10","author":"Ingelsson","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib103","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib104","series-title":"13th International Conference on Alzheimer's and Parkinson's Diseases, Neurodegener Dis, Vienna, Austria","article-title":"Randomized, double-blind, placebo-controlled, single ascending dose study of anti-alpha-synuclein antibody BIIB054 in healthy volunteers [abstract]","author":"Brys","year":"2017"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib105","author":"Alzforum"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib106","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/NEN.0000000000000018","article-title":"Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies","volume":"72","author":"Colom-Cadena","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib107","first-page":"216","article-title":"Regional overlap of pathologies in Lewy body disorders","volume":"76","author":"Colom-Cadena","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib108","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.neurobiolaging.2012.06.015","article-title":"MAPT H1 haplotype is associated with enhanced alpha-synuclein deposition in dementia with Lewy bodies","volume":"34","author":"Colom-Cadena","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib109","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/brain\/124.7.1438","article-title":"The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK","volume":"124","author":"Nath","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0072-9752(07)01242-0","article-title":"The epidemiology of progressive supranuclear palsy","volume":"89","author":"Golbe","year":"2008","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib111","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","article-title":"Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia","volume":"10","author":"Steele","year":"1964","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib112","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib113","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.neuron.2016.04.042","article-title":"Increased 4R-tau induces pathological changes in a human-tau mouse model","volume":"90","author":"Schoch","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib114","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/B978-0-12-802395-2.00025-0","volume":"145","author":"Kovacs","year":"2017","journal-title":"Tauopathies, Handb Clin Neurol"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib115","first-page":"23","article-title":"Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life","volume":"92","author":"Rebeiz","year":"1967","journal-title":"Trans. Am. Neurol. Assoc."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib116","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib117","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/21678707.2017.1335596","article-title":"Therapeutic options for Progressive Supranuclear Palsy including investigational drugs","volume":"5","author":"Shoeibi","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib118","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","article-title":"Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes","volume":"86","author":"Coyle-Gilchrist","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib119","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00001756-200104170-00014","article-title":"Intracellular processing of aggregated tau differs between corticobasal degeneration and progressive supranuclear palsy","volume":"12","author":"Arai","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ana.10793","article-title":"Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration","volume":"55","author":"Arai","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib121","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1440-1789.2003.00543.x","article-title":"Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration","volume":"24","author":"Wakabayashi","year":"2004","journal-title":"Neuropathology"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib122","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/13543784.2018.1460356","article-title":"Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy","volume":"27","author":"Shoeibi","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib123","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib124","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/S0002-9440(10)61154-6","article-title":"Signature tau neuropathology in gray and white matter of corticobasal degeneration","volume":"160","author":"Forman","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib125","doi-asserted-by":"crossref","first-page":"23645","DOI":"10.1074\/jbc.M703269200","article-title":"Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis","volume":"282","author":"Hanger","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib126","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ncomms1255","article-title":"The acetylation of tau inhibits its function and promotes pathological tau aggregation","volume":"2","author":"Cohen","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib127","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/brain\/aws013","article-title":"Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies","volume":"135","author":"Irwin","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13024-017-0181-0","article-title":"Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice","volume":"12","author":"Hastings","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib129","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00401-002-0587-8","article-title":"Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration","volume":"104","author":"Ferrer","year":"2002","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib130","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib131","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clineuro.2016.04.021","article-title":"Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy","volume":"146","author":"Leclair-Visonneau","year":"2016","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib132","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib133","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib134","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease","volume":"101","author":"Liu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib135","series-title":"Alzheimer's Association International Conference (AAIC)","first-page":"261","article-title":"Early clinical results and preclinical validation of the O-GlcNAcase (OGA) inhibitor MK-8719 as a novel therapeutic for the treatment of tauopathies [abstract]","author":"Smith","year":"2016"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib136","series-title":"Alzheimer's Association International ConferenceChicago, US","article-title":"Phase 1 study in healthy volunteers of the O-glcnacase inhibitor ASN120290 as a novel therapy for progressive supranuclear palsy and related tauopathies [abstract]","author":"Ryan","year":"2018"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib137","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ncb1901","article-title":"Transmission and spreading of tauopathy in transgenic mouse brain","volume":"11","author":"Clavaguera","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib138","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1073\/pnas.1301175110","article-title":"Brain homogenates from human tauopathies induce tau inclusions in mouse brain","volume":"110","author":"Clavaguera","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib139","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.neuron.2014.04.047","article-title":"Distinct tau prion strains propagate in cells and mice and define different tauopathies","volume":"82","author":"Sanders","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib140","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1523\/JNEUROSCI.1230-17.2017","article-title":"Pathological tau strains from human brains Recapitulate the diversity of tauopathies in nontransgenic mouse brain","volume":"37","author":"Narasimhan","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib141","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib142","doi-asserted-by":"crossref","first-page":"19855","DOI":"10.1074\/jbc.R114.549295","article-title":"Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target","volume":"289","author":"Holmes","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195211","article-title":"Novel monoclonal antibodies targeting the microtubule-binding domain of human tau","volume":"13","author":"Croft","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib144","series-title":"Movement Disorders","first-page":"857","article-title":"Chapter 56 - tau protein: biology and pathobiology","author":"Kanaan","year":"2015"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib145","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.1113694","article-title":"Tau suppression in a neurodegenerative mouse model improves memory function","volume":"309","author":"Santacruz","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib146","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.3233\/JAD-2004-6S605","article-title":"The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection","volume":"6","author":"Gozes","year":"2004","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib147","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2009.02.011","article-title":"NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model","volume":"34","author":"Shiryaev","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib148","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib149","author":"Boxer","year":"2017"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib150","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nm.4011","article-title":"Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling","volume":"22","author":"Myeku","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib151","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-016-0292-9","article-title":"Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy","volume":"4","author":"Piras","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib153","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1046\/j.1471-4159.2000.0751681.x","article-title":"Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy","volume":"75","author":"Swerdlow","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib154","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/jcbfm.2009.2","article-title":"In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy","volume":"29","author":"Stamelou","year":"2009","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib155","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.redox.2017.03.008","article-title":"Mitochondrial hyperpolarization in iPSC-derived neurons from patients of FTDP-17 with 10+16 MAPT mutation leads to oxidative stress and neurodegeneration","volume":"12","author":"Esteras","year":"2017","journal-title":"Redox Biol"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib156","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mds.22023","article-title":"Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial","volume":"23","author":"Stamelou","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib157","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1212\/NXI.0000000000000266","article-title":"CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial","volume":"3","author":"Apetauerova","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib158","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1523\/JNEUROSCI.3637-10.2010","article-title":"Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice","volume":"30","author":"Piedrahita","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib159","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/jnc.12203","article-title":"AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans","volume":"125","author":"Georgievska","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib160","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1007\/s11064-016-1960-7","article-title":"RNA interference silencing of glycogen synthase kinase 3beta inhibites tau phosphorylation in mice with alzheimer disease","volume":"41","author":"Bian","year":"2016","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib161","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1523\/JNEUROSCI.2336-15.2016","article-title":"Rho kinase inhibition as a therapeutic for progressive supranuclear palsy and corticobasal degeneration","volume":"36","author":"Gentry","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib162","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1038\/s41598-017-07906-1","article-title":"Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's disease","volume":"7","author":"Croft","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib163","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2174\/1567205011666141107150331","article-title":"Structure and mechanism of action of tau aggregation inhibitors","volume":"11","author":"Cisek","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib164","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nchem.2889","article-title":"Structure-based inhibitors of tau aggregation","volume":"10","author":"Seidler","year":"2018","journal-title":"Nat. Chem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib165","doi-asserted-by":"crossref","first-page":"42986","DOI":"10.1074\/jbc.M105113200","article-title":"Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17","volume":"276","author":"Kalbfuss","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib166","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.30","article-title":"Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies","volume":"3","author":"Sud","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib167","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/156652321405140926160602","article-title":"Tau silencing by siRNA in the P301S mouse model of tauopathy","volume":"14","author":"Xu","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib168","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/369488a0","article-title":"Altered microtubule organization in small-calibre axons of mice lacking tau protein","volume":"369","author":"Harada","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2007.05.010","article-title":"Knock-out and transgenic mouse models of tauopathies","volume":"30","author":"Denk","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib170","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1523\/JNEUROSCI.2107-13.2013","article-title":"Antisense reduction of tau in adult mice protects against seizures","volume":"33","author":"DeVos","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib171","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/jnen\/60.6.647","article-title":"Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration","volume":"60","author":"Ishizawa","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib172","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mds.20668","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy","volume":"21","author":"Gerhard","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib173","article-title":"Immune-related genetic enrichment in frontotemporal dementia: an analysis of genome-wide association studies","volume":"15","author":"Broce","year":"2018","journal-title":"PLoS Med."},{"issue":"22","key":"10.1016\/j.parkreldis.2018.10.006_bib174","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005610","article-title":"[(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy","volume":"90","author":"Passamonti","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib175","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib176","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1756285610375328","article-title":"Multiple system atrophy: current and future approaches to management","volume":"3","author":"Flabeau","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib177","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/awh488","article-title":"Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism","volume":"128","author":"Williams","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib178","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jnnp.64.2.184","article-title":"Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination","volume":"64","author":"Wenning","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib179","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/brain\/awq123","article-title":"Does corticobasal degeneration exist? A clinicopathological re-evaluation","volume":"133","author":"Ling","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib180","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s10072-015-2226-x","article-title":"Corticobasal degeneration: clinical characteristics and multidisciplinary therapeutic approach in 26 patients","volume":"36","author":"Shehata","year":"2015","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib181","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/mds.21578","article-title":"Levodopa responsiveness in disorders with parkinsonism: a review of the literature","volume":"22","author":"Constantinescu","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib182","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/mds.23192","article-title":"Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry","volume":"25","author":"Kollensperger","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib183","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/mds.22322","article-title":"Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies","volume":"23","author":"Goldman","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib184","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.870120203","article-title":"Multiple system atrophy: a review of 203 pathologically proven cases","volume":"12","author":"Wenning","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib185","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40263-016-0347-2","article-title":"A review of treatment options for progressive supranuclear palsy","volume":"30","author":"Stamelou","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib186","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11940-016-0422-5","article-title":"Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options","volume":"18","author":"Lamb","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib187","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMra1311488","article-title":"Multiple-system atrophy","volume":"372","author":"Fanciulli","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib188","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/mds.26334","article-title":"Therapeutic advances in multiple system atrophy and progressive supranuclear palsy","volume":"30","author":"Poewe","year":"2015","journal-title":"Mov. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2018.10.006_bib189","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.parkreldis.2015.09.023","article-title":"Therapeutic interventions in parkinsonism: corticobasal degeneration","volume":"22","author":"Marsili","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.autneu.2017.10.006","article-title":"Symptomatic therapy of multiple system atrophy","volume":"211","author":"Rohrer","year":"2018","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib191","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2016.01.005","article-title":"Outcome of deep brain stimulation in slowly progressive multiple system atrophy: a clinico-pathological series and review of the literature","volume":"24","author":"Meissner","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2018.10.006_bib192","series-title":"Dementia with Lewy Bodies and Parkinson's Disease Dementia Subjects Experiencing Visual Hallucinations [abstract], 69th AAN Annual meeting, Neurology, Boston, Massachusetts, USA","article-title":"A phase 2 study of Nelotanserin, a novel 5HT2A Receptor inverse agonist","author":"Wen","year":"2017"},{"key":"10.1016\/j.parkreldis.2018.10.006_bib193","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","article-title":"Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study","volume":"90","author":"Murata","year":"2018","journal-title":"Neurology"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018304322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018304322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:21:45Z","timestamp":1761099705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018304322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":192,"alternative-id":["S1353802018304322"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.10.006","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in the treatment of Parkinson-Plus syndromes","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}